And the timing is, we will provide update when we get closer, but the community is receptive to this. We are engaging with the community as we speak and also we mentioned that we are presenting at the conference in June in Colorado, as a matter of fact, to connect with the community about the next steps of this trial.
Tom Bishop: And you don’t quite yet know the number in the trial, which would affect how long it takes to go on?
Dr. Christopher Missling: So the good news is that it’s a relatively short trial. It’s 12 weeks, so it’s not too long. It can be done relatively timely, because the matter of fact is it’s a not long trial to begin with. And if there is, again, ability to scale this up and there’s strong interest in an alternative marketed drug to Rett syndrome patients, this could help actually accelerate this trial to start and to kick off. Again, we will provide update as we know more.
Tom Bishop: Okay. Can you remind us of the Fragile X data to-date? Is it just Phase 1 kind of safety data or in food data or is it — or do I forget kind of some trial results we’ve gotten that you’re considering moving to Phase 2b/3 trial?
Dr. Christopher Missling: Which indication? Sorry, I missed that.
Tom Bishop: Fragile X.
Dr. Christopher Missling: Yeah. So this is very intriguing data. It’s a biomarker, which is measurable both in patients, in humans, as well as in animals. And it’s correlating very clearly, it has been published to the pathology of Fragile X or to showing a reduction of the pathology of Fragile X. And this will be presented for the first time at the conference in July and we’re very excited about it, because it strengthens the, first of all, the evidence that Fragile X is an extremely good indication for blarcamesine for ANAVEX2-73, but also it would give us in a clinical trial, a biomarker, which is so important in CNS, which is hard to find biomarkers of a pathology. So these are the two reasons why we’re very excited about this presentation coming up.
Tom Bishop: So you could move into a potentially pivotal Phase 2b/3 trial, just based on your biomarker data to date, is it?
Dr. Christopher Missling: Yeah. So that biomarker data we presented will also — we also — yeah, we have to also appreciate that there are physicians, patients, advocates group who want to learn why would you — why want to be part of a trial? And this information would give somebody that information to say, to be excited about being part of a trial because of the fact that it would define the chances of being beneficial to a Fragile X patient in real world and that’s what this biomarker data will — would be to get the excitement in the community to also then have a smooth enrollment and trial execution, which is important.
Tom Bishop: Okay. Finally, I just wanted to ask, I worry about, I never thought we’d see stock — the stock under 5 again, let alone 4. And I’m wondering if this could be concerned about the delay in the peer reviewed article that we’ve been anticipating for so long and possibly even the lack of any insider buying. I mean, is there something preventing legally the company from doing insider buying, and if not, I would highly encourage it to show some faith here?
Dr. Christopher Missling: Yeah. I appreciate the feedback. We are, of course, not happy about it either, but it’s, we have to also be aware that the whole market is in challenging positions. But the fortunate thing for us is that we have really enough cash without any debt. We have a very good team which can execute. We also hired additional team members and we’re very — we’re expanding in our execution of trials, which we pointed out also today and we are really excited and moving forward. And so that’s the part we can do and that’s what we will do. So it’s not — it would be futile to comment on the stock market.
Tom Bishop: Oh! I mean, is there any chance of some insider buying? Is there some, have you, the lawyers telling you, you can’t do it?
Dr. Christopher Missling: Every director is, insider has the chance to buy it when we have a window. We have to check if we have a window. If we do have a window, this is a choice for every Board member or insider to do.
Tom Bishop: Thank you. I was just wondering if the window is now closed and that’s why we’re not seeing?
Dr. Christopher Missling: It’s right now closed, but it could open. So we will see.
Tom Bishop: All right. Thank you.
Dr. Christopher Missling: Thank you.
Operator: Looks like that’s all the questions today, Dr. Missling.
Dr. Christopher Missling: Thank you. And in closing, we remain committed to the development of our programs within neurodegenerative, neurodevelopmental and neuropsychiatric disorders, which could further expand our portfolio of transformative investigational therapies, utilizing our differentiated precision medicine platform to deliver easy access and scalable treatment options for brain disorders. We continue to focus on execution and commercial readiness as we advance our therapeutic pipeline to potentially improve patient lives living with these devastating conditions. Thank you very much.
Operator: Great. Thank you, ladies and gentlemen. That concludes today’s conference call. We appreciate your participation. You’re now welcome to disconnect.
